DC-based anticancer vaccines could potentially deliver tumour-associated antigens to lymphoid tissues and induce the activation of antigen-specific CD4+ and CD8+ T cells that can home to neoplastic lesions and mediate tumour regression. This evidence concerns the gene CD8A and neoplasm.